[go: up one dir, main page]

MX2020006468A - Composiciones y metodos para el tratamiento o prevencion de sintomas vasomotores. - Google Patents

Composiciones y metodos para el tratamiento o prevencion de sintomas vasomotores.

Info

Publication number
MX2020006468A
MX2020006468A MX2020006468A MX2020006468A MX2020006468A MX 2020006468 A MX2020006468 A MX 2020006468A MX 2020006468 A MX2020006468 A MX 2020006468A MX 2020006468 A MX2020006468 A MX 2020006468A MX 2020006468 A MX2020006468 A MX 2020006468A
Authority
MX
Mexico
Prior art keywords
compositions
treating
methods
vasomotor symptoms
preventing vasomotor
Prior art date
Application number
MX2020006468A
Other languages
English (en)
Inventor
Joseph M Palumbo
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2020006468A publication Critical patent/MX2020006468A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción está dirigida a composiciones que comprenden como un ingrediente activo, una dosis más baja de ácido 4-({(1-ciclopropilisoquinolin-3-il)[4- (trifluorometoxi)benc il]amino}sulfonil)benzoico o una sal farmacéuticamente aceptable del mismo para tratar o prevenir los síntomas vasomotores en un sujeto, y métodos que comprenden administrar dicho compuesto o la sal farmacéuticamente aceptable del mismo a una dosis más baja, respectivamente.
MX2020006468A 2017-12-19 2018-12-18 Composiciones y metodos para el tratamiento o prevencion de sintomas vasomotores. MX2020006468A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607666P 2017-12-19 2017-12-19
PCT/JP2018/046544 WO2019124366A1 (en) 2017-12-19 2018-12-18 Compositions and methods for treating or preventing vasomotor symptoms

Publications (1)

Publication Number Publication Date
MX2020006468A true MX2020006468A (es) 2021-01-08

Family

ID=65023968

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006468A MX2020006468A (es) 2017-12-19 2018-12-18 Composiciones y metodos para el tratamiento o prevencion de sintomas vasomotores.

Country Status (16)

Country Link
US (3) US11471452B2 (es)
EP (2) EP3727383A1 (es)
JP (2) JP7265551B2 (es)
KR (1) KR20200100746A (es)
CN (1) CN111465395A (es)
AR (1) AR113963A1 (es)
AU (1) AU2018391882A1 (es)
BR (1) BR112020012111A2 (es)
CA (1) CA3085292A1 (es)
CO (1) CO2020007091A2 (es)
IL (1) IL275258A (es)
MX (1) MX2020006468A (es)
PH (1) PH12020550932A1 (es)
SG (1) SG11202005383RA (es)
TW (1) TW201929855A (es)
WO (1) WO2019124366A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013023330B8 (pt) 2011-03-16 2022-09-27 Mitsubishi Tanabe Pharma Corp Compostos de sulfonamida tendo atividade antagonista trpm8
BR112013033316A2 (pt) * 2011-06-24 2017-01-31 Amgen Inc antagonista de trpm8 e seu uso em tratamentos
JP5985453B2 (ja) 2012-09-14 2016-09-06 田辺三菱製薬株式会社 医薬組成物
WO2014042238A1 (ja) 2012-09-14 2014-03-20 田辺三菱製薬株式会社 スルホンアミド化合物
CA2959231C (en) 2013-10-22 2022-06-21 Edward Tak Wei Di-isopropyl-phosphinoyl-alkane (dapa) compounds as topical agents for the treatment of sensory discomfort
ES2957232T3 (es) * 2016-06-13 2024-01-15 Mitsubishi Tanabe Pharma Corp Composiciones para el tratamiento o la prevención de síntomas vasomotores

Also Published As

Publication number Publication date
PH12020550932A1 (en) 2021-05-10
US20220401434A1 (en) 2022-12-22
IL275258A (en) 2020-07-30
JP7265551B2 (ja) 2023-04-26
KR20200100746A (ko) 2020-08-26
CO2020007091A2 (es) 2020-06-19
US11471452B2 (en) 2022-10-18
US20200383968A1 (en) 2020-12-10
AU2018391882A2 (en) 2022-06-23
WO2019124366A1 (en) 2019-06-27
EP3727383A1 (en) 2020-10-28
JP2021506881A (ja) 2021-02-22
TW201929855A (zh) 2019-08-01
US20250057831A1 (en) 2025-02-20
CA3085292A1 (en) 2019-06-27
JP2023089175A (ja) 2023-06-27
SG11202005383RA (en) 2020-07-29
AR113963A1 (es) 2020-07-01
BR112020012111A2 (pt) 2020-11-24
EP4059500A1 (en) 2022-09-21
CN111465395A (zh) 2020-07-28
AU2018391882A1 (en) 2020-07-02
RU2020123723A (ru) 2022-01-20

Similar Documents

Publication Publication Date Title
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
GEAP201814248A (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA201691402A1 (ru) Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты
PH12016502103A1 (en) Novel disubstituted 1,2, 4-triazine compound
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2020013311A (es) Composicion farmaceutica para administracion topica.
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
EA201692300A1 (ru) Производные карбоксамида
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
EA201692298A1 (ru) Производные карбоксамидов
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
MX372773B (es) Ácido (2s, 4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico.
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
EA202091293A1 (ru) Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
PH12020550932A1 (en) Compositions and methods for treating or preventing vasomotor symptoms